Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broad Medicare Formularies Would Negatively Impact Rx Industry, PCMA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Limiting PBMs’ ability to control costs in Medicare Rx would benefit advocates of a government-run health care system, Pharmaceutical Care Management Association CEO Merritt says. Broad drug formularies also would increase costs for employers, he says.

You may also be interested in...



Employer Drug Coverage Will Shift To Part D, Stakeholders Say

Companies will accept the government subsidy for retirees’ drug coverage initially, but will move former workers to the Medicare drug benefit in later years, executives from Kaiser Foundation Health Plans and the Employers Coalition on Medicare predict.

USP Still Discussing Structure Of Medicare Rx Formulary Guidelines

U.S. Pharmacopeia is aware of speculation that it will elevate the “recommended subdivisions” in its draft guidelines to classes in the final model, but says it has not made a decision and that its expert committee is still discussing the issue.

USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel